BioCryst Pharmaceuticals Inc (BCRX.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|75||2017||Chairman of the Board|
|57||2007||President, Chief Executive Officer, Director|
|50||2018||Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer, IR Contact Officer|
|65||2013||Senior Vice President - Drug Discovery|
|51||2015||Senior Vice President, Chief Commercial Officer|
- BRIEF-Biocryst Pharmaceuticals Q1 Loss Per Share $0.26
- BRIEF-BioCryst Receives European Medicines Agency Approval For Alpivab For Treatment Of Influenza
- BRIEF-Biocryst Pharmaceuticals And Idera Pharmaceuticals Reschedule Meetings To Vote On Proposed Merger
- BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst
- BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals